Company intelligence / Profile preview

RoverMed BioSciences

St. Cloud, Minnesota, United States

Ownership: Private
Development stage: Other

Overview

RoverMed BioSciences developed a non-viral nanocapsule delivery technology capable of transporting large or small molecules, naked DNA, and viral particles across biological barriers into the nuclei of diseased cells while sparing healthy cells; its assets were acquired by Asklepios BioPharmaceutical (AskBio) in 2019 for integration into AskBio’s AAV gene therapy platform, and there is no evidence of independent clinical-stage programs.

Therapeutic areas: Rare Diseases
Modalities: NanoparticleNanocapsuleSmall molecule (via delivery platform)Biologic (via delivery platform)Naked DNA (via delivery platform)Viral vector (via delivery platform)
Industry: Drug Discovery Services

Partnerships

Asklepios BioPharmaceutical (technology asset acquisition and integration into AAV gene therapy platform)

Beyond the preview

Go deeper on RoverMed BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RoverMed BioSciences.

Explore the full profile